ArticleCell communication and signaling : CCS2026
KTX207-mediated PDE4D degradation disrupts tumour cell migration, invasion, and angiogenic potential.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPhosphodiesterase 4 (PDE4) enzymes regulate intracellular cyclic adenosine monophosphate (cAMP) and thereby influence multiple cancer-relevant processes. Metastasis and angiogenesis, which rely on coordinated cytoskeletal remodelling and integrin-mediated signalling are key determinants of cancer progression. We previously reported KTX207, a cereblon-based proteolysis-targeting chimera (PROTAC) that selectively degrade PDE4D shortforms and suppresses tumour cell proliferation.
methodsTo further evaluate the therapeutic potential of KTX207, we examined the effects of PDE4D degradation on cancer cell migration, invasion, cytoskeletal organisation, and angiogenic capacity using 2D and 3D models. Assays included wound healing, Boyden chamber invasion, single-cell tracking, 3D spheroid invasion, endothelial tube formation and sprouting assays, as well as immunocytochemistry, Western blotting, and ELISA. Proteasome inhibition was used to assess degradation dependency.
resultsKTX207 markedly impaired A549 cell motility, abrogated directional persistence, disrupted cytoskeletal architecture with mislocalisation of focal adhesion kinase, and reduced invasive capability. Endothelial cells exhibited reduced angiogenic and sprouting potential. KTX207 altered key regulators of focal adhesion and cytoskeletal signalling, including integrin β1, ezrin, RhoA, and phospho‑Src, and reduced angiogenic factors such as VEGF‑A and angiopoietin‑2. Phospho-FAK levels remained unchanged, indicating disruption of spatial rather than global kinase signalling. Importantly, these effects were attenuated by proteasome inhibition, supporting a degradation-dependent mechanism.
conclusionThese findings highlight a previously underappreciated role for PDE4D shortforms in coordinating cytoskeletal dynamics and tumour-associated angiogenesis. Targeted PDE4D degradation therefore represents a promising therapeutic strategy for limiting metastatic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.